Tuesday, December 8, US pharmaceutical giant Johnson & Johnson plans to provide 500 million doses of its coronavirus vaccine for poor countries once results of clinical trials are announced by the end of January.
It plans to sell the vaccine at cost price and will provide the doses to Gavi, the Vaccine Alliance, the group’s scientific director Paul Stoffels told a virtual round table in Geneva.
Currently, the vaccine is undergoing final-stage clinical trials involving 60,000 participants at more than 200 locations in the US and other countries. Results are expected in late January.
J&J’s Stoffels said the firm’s Phase III trials — which had to be interrupted briefly when one subject fell ill — are now “in full swing”, adding: “We target for results the month of January for efficacy and safety.”